AstraZeneca, following global outrage over the side effects of the vaccine, said on Tuesday that the benefits of the vaccine “far outweigh” the risks of “extremely rare” potential side effects. - Benefits Of Covishield COVID Vaccine Far Outweigh Extremely Rare Potential Side Effects: AstraZeneca
AstraZeneca has stressed that patient safety is its "highest priority" and pointed out that regulators around the world “consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects".
Covaxin Shows 81% Efficacy In Phase 3 Trials, Also Works Against Virus Variants: Bharat Biotech
Covaxin demonstrates high clinical efficacy trend against Covid-19 but also significant immunogenicity against the rapidly emerging variants, said MD and Chairperson of Bharat Biotech. File Photo Outlook Web Bureau 2021-03-03T18:00:56+05:30 Covaxin Shows 81% Efficacy In Phase 3 Trials, Also Works Against Virus Variants: Bharat Biotech outlookindia.com 2021-03-03T18:35:56+05:30
Also read
After releasing the results of Phase 3 clinical trials of its Covid-19 vaccine on Wednesday, Bharat Biotech said that its Covid-19 vaccine, known as Covaxin, has demonstrated an interim vaccine efficacy of 81 per cent in Phase 3 clinical trials.
A World Health Organization panel has recommended wide use of Oxford-AstraZeneca Covid vaccine including in countries where the South African variant of the coronavirus may reduce its efficacy.